Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Povetacicept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Povetacicept is under development for the treatment of systemic lupus erythematosus, membranous glomerulonephritis, Sjogren's syndrome, IgA nephropathy (Berger''s Disease), lupus nephritis, immune thrombocytopenia, acquired (autoimmune) hemolytic anemia. It is administered through intravenous and subcutaneous route. The drug candidate is an engineered B-cell modulator. It acts by targeting BAFF and APRIL.
It was also under development for pemphigus foliaceus, pemphigus vulgaris and bullous pemphigoid.
Alpine Immune Sciences overview
Alpine Immune Sciences (Alpine), formerly Nivalis Therapeutics Inc, is a pharmaceutical company. The company focuses on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The company also provides ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer. It offers a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Alpine is headquartered in Seattle, Washington, the US.
For a complete picture of Povetacicept’s drug-specific PTSR and LoA scores, buy the report here.